MedPath

A Study of DF6002 Alone and in Combination With Nivolumab

Phase 1
Recruiting
Conditions
Solid Tumors
Interventions
Registration Number
NCT04423029
Lead Sponsor
Dragonfly Therapeutics
Brief Summary

The purpose of this study is to evaluate the safety, tolerability, drug-levels, drug-effects and preliminary anti-tumor activity of DF6002 alone and in combination with Nivolumab in participants with advanced solid tumors.

Detailed Description

Assess the safety and tolerability of subcutaneous (SC) and intravenous (IV) administration of DF6002, as monotherapy and in combination with nivolumab, and to determine the maximum tolerated dose (MTD) and recommended efficacy expansion dose (REED) of SC and IV DF6002, both as monotherapy and in combination with nivolumab, for patients with advanced (unresectable, recurrent, or metastatic) solid tumors.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
438
Inclusion Criteria
  • Advanced/metastatic solid tumors, for which no standard therapy exists or standard therapy has failed among the following tumor types: melanoma, non-small cell lung cancer, small cell lung cancer, head and neck squamous cell, urothelial, gastric, esophageal, cervical, hepatocellular, merkel cell, cutaneous squamous cell carcinoma, renal cell, endometrial, triple-negative breast, ovarian, and prostate
  • ECOG performance status of 0 or 1
  • Clinical or radiological evidence of disease
  • Adequate hematological, hepatic and renal function
  • Anticoagulants are required for the following: Khorana Risk Score ≥ 2 or as assessed by Investigator as being at high risk for venous thromboembolism (VTE) or history of VTE ≥ 6 months from enrollment
Exclusion Criteria
  • Concurrent anticancer treatment (with the exception of palliative bone directed radiotherapy), immune therapy, or cytokine therapy (except for erythropoietin), major surgery (excluding prior diagnostic biopsy), concurrent systemic therapy with steroids or other immunosuppressive agents, or use of any investigational drug within 28 days before the start of study treatment
  • Prior treatment with DF6002, recombinant human interleukin-12 (rhIL-12)-directed therapy, or any drug containing an interleukin-12 (IL-12) moiety
  • Previous malignant disease other than the current target malignancy within the last 3 years, with the exception of basal or squamous cell carcinoma of the skin, localized prostate cancer or cervical carcinoma in situ
  • Rapidly progressive disease
  • Serious cardiac illness or medical conditions
  • Known diagnosis of antiphospholipid syndrome or clinically significant hereditary thrombophilia

Other protocol-defined inclusion/exclusion criteria apply

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Dose Escalation / Monotherapy / Subcutaneously or IntravenouslyDF6002Subcutaneous portion of the study is complete. Dosing DF6002 Q4W
Dose Escalation / Combination / Subcutaneously or IntravenouslyDF6002Subcutaneous portion of the study is complete. Dosing DF6002 Q4W Dosing nivolumab Q4W
Dose Escalation / Combination / Subcutaneously or IntravenouslyNivolumabSubcutaneous portion of the study is complete. Dosing DF6002 Q4W Dosing nivolumab Q4W
Safety/PK/PD / Combination / Subcutaneously or IntravenouslyNivolumabSubcutaneous portion of the study is complete. Dosing DF6002 Q4W Dosing nivolumab Q4W
Efficacy Expansion / Combination / Subcutaneously or Intravenously / MelanomaNivolumabSubcutaneous portion of the study is complete. 2L+ melanoma Dosing DF6002 Q4W Dosing nivolumab Q4W
Efficacy Expansion / Combination / Subcutaneously or Intravenously / Non-MelanomaNivolumabSubcutaneous portion of the study is complete. 2L+ non-melanoma skin cancer (including cSCC, BCC, and MCC) Dosing DF6002 Q4W Dosing nivolumab Q4W
Safety/PK/PD / Monotherapy / Subcutaneously or IntravenouslyDF6002Subcutaneous portion of the study is complete. Dosing DF6002 Q4W
Safety/PK/PD / Combination / Subcutaneously or IntravenouslyDF6002Subcutaneous portion of the study is complete. Dosing DF6002 Q4W Dosing nivolumab Q4W
Efficacy Expansion / Combination / Subcutaneously or Intravenously / MelanomaDF6002Subcutaneous portion of the study is complete. 2L+ melanoma Dosing DF6002 Q4W Dosing nivolumab Q4W
Efficacy Expansion / Combination / Subcutaneously or Intravenously / Non-MelanomaDF6002Subcutaneous portion of the study is complete. 2L+ non-melanoma skin cancer (including cSCC, BCC, and MCC) Dosing DF6002 Q4W Dosing nivolumab Q4W
Primary Outcome Measures
NameTimeMethod
Number of participants with dose-limiting toxicities (DLTs)During the first 3 weeks of treatment

Dose Escalation

Overall Response Rate (ORR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 per an Independent Endpoint Review Committee (IERC)Up to 2 years

Efficacy Expansion Arms

Secondary Outcome Measures
NameTimeMethod
Severity of TEAEsUp to 2 years

Severity of the TEAEs seen in study participants

Clinical benefit rate (CBR) according to RECIST 1.1 per Investigator assessmentUp to 2 years

Overall change, if any, after treatment

Overall Survival (OS)Up to 5 years

Phase 2 only

Amount of Treatment Emergent Adverse Events (TEAEs)Up to 2 years

Number of participants with TEAEs

Duration of TEAEsUp to 2 years

How long the TEAEs seen last

Number of participants with changes from baseline in clinical laboratory parametersUp to 2 years

Overall change, if any, after treatment

Number of participants with changes from baseline in electrocardiogram (ECG) parametersUp to 2 years

Overall change, if any, after treatment

Number of participants with changes from baseline in vital sign parametersUp to 2 years

Overall change, if any, after treatment

Duration of Response (DOR) according to RECIST 1.1 per Investigator assessmentUp to month 24

Overall change, if any, after treatment

Area under the plasma concentration-time curve from the time of dosing to the time of the last observation (AUC 0-T)Up to day 28

Overall change, if any, after treatment

Area under the plasma concentration-time curve from the time of dosing extrapolated to infinity (AUC 0-INF)Up to day 28

Overall change, if any, after treatment

Maximum serum concentration observed post-dose (Cmax)Up to day 28

Overall change, if any, after treatment

Best overall response (BOR) according to RECIST 1.1 per Investigator assessmentApproximately one year

Overall change, if any, after treatment

Confirmed ORR per RECIST 1.1 per Investigator assessmentUp to 2 years

Phase 1/1b only

Progression-free survival (PFS) according to RECIST 1.1 per Investigator assessmentUp to 2 years

Phase 2 only

CBR according to RECIST 1.1 per IERCUp to 2 years

Phase 2 only

PFS according to RECIST 1.1 per IERCUp to 2 years

Phase 2 only

DOR according to RECIST 1.1 per IERCUp to month 24

Phase 2 only

Unconfirmed response after 4 cycles according to RECIST 1.1Up to 2 years

Phase 2 only

Serum titers of anti-DF6002 antibodiesUp to 2 years

Phase 2 only

Serum titers of anti-nivolumab antibodiesUp to 2 years

Phase 2 only

Trial Locations

Locations (32)

Hospital Universitari Vall d'Hebrón

🇪🇸

Barcelona, Spain

Clinica Universidad de Navarra - Madrid

🇪🇸

Madrid, Spain

START Madrid - Hospital Universitario Fundación Jiménez Díaz

🇪🇸

Madrid, Spain

Clinica Universidad de Navarra - Pamplona

🇪🇸

Pamplona, Spain

Local Institution - 0022

🇦🇺

Heidelberg, Australia

Hôpital Saint-Louis

🇫🇷

Paris, France

Centre Hospitalier Lyon-Sud

🇫🇷

Pierre-Benite, France

Gustave Roussy

🇫🇷

Villejuif, France

Local Institution - 0023

🇦🇺

Box Hill, Australia

SCRI - HealthOne Denver

🇺🇸

Denver, Colorado, United States

Hospital Universitario Ramón y Cajal

🇪🇸

Madrid, Spain

University of California Irvine

🇺🇸

Orange, California, United States

Institut Bergonié

🇫🇷

Bordeaux Cedex, France

Yale School of Medicine

🇺🇸

New Haven, Connecticut, United States

University of Miami

🇺🇸

Miami, Florida, United States

Augusta University Georgia Cancer Center

🇺🇸

Augusta, Georgia, United States

University of Iowa Hospitals and Clinics

🇺🇸

Iowa City, Iowa, United States

Local Institution

🇺🇸

Boston, Massachusetts, United States

Barbara Ann Karmanos Cancer Institute

🇺🇸

Detroit, Michigan, United States

Henry Ford Hospital

🇺🇸

Detroit, Michigan, United States

HealthPartners Cancer Center at Regions Hospital

🇺🇸

Saint Paul, Minnesota, United States

Atlantic Health System

🇺🇸

Morristown, New Jersey, United States

Montefiore Medical Center

🇺🇸

Bronx, New York, United States

Roswell Park Comprehensive Cancer Center

🇺🇸

Buffalo, New York, United States

University Hospitals Cleveland Medical Center

🇺🇸

Cleveland, Ohio, United States

Stephenson Cancer Center

🇺🇸

Oklahoma City, Oklahoma, United States

Rhode Island Hospital

🇺🇸

Providence, Rhode Island, United States

SCRI - Tennessee Oncology - Saint Thomas West Clinic

🇺🇸

Nashville, Tennessee, United States

University of Texas MD Anderson Cancer Center

🇺🇸

Houston, Texas, United States

Huntsman Cancer Institute and Hospital

🇺🇸

Salt Lake City, Utah, United States

USOR - Virginia Cancer Specialists - Fairfax Office

🇺🇸

Fairfax, Virginia, United States

Froedtert Hospital

🇺🇸

Milwaukee, Wisconsin, United States

© Copyright 2025. All Rights Reserved by MedPath